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Available online 8 August 2015AbstractMyofacial pain syndrome (MPS) is a disorder which has become a topic over the past two decades and nowadays .10 patients
(9 female& 1 male) complaining of unilateral MPS were injected with botulinum toxin type A(BTX-A) in masseter and temporalis
muscles extra orally under electromyographic guidance (EMG) since they are the primary muscles responsible for pain in ear region
and temporal headache respectively, which cause limitation of mandibular movement and development of MPS. EMG evaluation of
the results together with clinical one were taken at baseline before injection, after 1, 2, 3 and 6 months following the last injection.
The study revealed that BTX-A reduced the severity of symptoms and improve functional abilities for patients with MPS and these
extend beyond its muscle - relaxing effects.
© 2015, Hosting by Elsevier B.V. on behalf of the Faculty of Dentistry, Tanta University.
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MPS is a disorder which has become a topic of
increasing interest over the past two decades, this
might be attributed to the fact that this disorder was
reported to affect at least 20% of all patients seen by
the dental practitioners [1,2].* Corresponding author. Tel.: þ20 01004624290.
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alideeb@yahoo.com (A.E. El-deeb).
Peer review under the responsibility of the Faculty of Dentistry,
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1687-8574/© 2015, Hosting by Elsevier B.V. on behalf of the Faculty of DMPS refers to a collection of symptoms associated
with functional and structural disturbances of tempo-
romandibular joint (TMJ) and masticatory muscles.
These symptoms more commonly include pain,
tenderness of TMJ and muscles of mastication, TMJ
sounds during condylar movements and limitation of
mandibular movements [3]. The great interest directed
toward MPS recently is due to, although it begins as a
functional muscular disorder, it ultimately can lead to
degenerative arthritis in TMJ [4e6].
The treatment of patients with MPS includes both
conservative which has gained a wide acceptance and
surgical procedures. It was generally accepted that the
predominant attitude toward treatment should beentistry, Tanta University.
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strable articular pathological conditions who have not
responded to usual conservative therapy are subjected
to surgery [7,8].
In the recent years, BTX-A1 has been successfully
used for treatment of different types of chronic pain
including, cervicogenic migraine, tension type and
chronic daily headaches and chronic pain related
muscular disorders [9e11]. Directing treatment to the
muscular component of MPS could yield important
therapeutic gains by new therapeutic agent which
possess high specificity as well as tolerable side ef-
fects. Accordingly, this study was planned to investi-
gate the effect of BTX-A as a minimally invasive
method for treatment of MPS.
2. Material and methods
10 patients (9 female & 1 male) randomly selected
from Out-Patient Clinic of the Oral and Maxillo Facial
Surgery Department, Faculty of Dentistry, Tanta Uni-
versity, their ages ranged from 19 to 50 years with a
mean of 32 years. They were assessed according to
criteria of Helkimo clinical dysfunction index (Di)
[12e15], clinical finding and surface electromyog-
raphy was used instead of needle electrodes which
regarded as invasive procedures in which needle elec-
trode is inserted through the skin into the muscles.
Either technique can be performed safely with accu-
racy confer the best results, but passive surface EMG
considered less invasive and less painful. The patients
were selected to fulfill the criteria of MPS proposed by
previous investigators, five of them were suffering
from painful clicking.
2.1. Electromyographic analysis
Surface electromyographic2 recording of masseter
and temporalis muscles were taken using 2-channel
EMG3 apparatus with input impedance 100 M U and
band width 2 Hze1 kHz gain 100e200 MV. Simulta-
neous recording of myoelectrical activity for both the
affected and the healthy side which was considered the
control side [16].
For masseter muscle, the active recording electrode
was placed over a motor point of the muscle and the
reference electrode was placed over the angle of the jaw.1 BTX-A: Botulinum toxin type A (Allergan, Inc., Iruine, CA,
USA).
2 Neuropak II (Nihon koden. Japan).For temporalis muscle, the active recording elec-
trode over motor point on the muscle and the reference
electrode were placed over a non-hair bearing area of
temporalis muscle. The amplitude of EMG signal
measured during maximal biting position (static test).
Surface EMG recording were taken from masseter
and temporalis muscles indicate hyperactivity of
muscles. EMG was taken at baseline before injection,
after 1, 2, 3 and 6 months following the last injection
EMG-Guided BTX-A injections in the hyperactive
masseter and temporalis muscles were performed via
an extra oral approach without anesthesia [17e20].
The injection was generally carried out at the same
visit. BTX-A was injected into the masseter and tem-
poralis muscles. One hundred units were reconstituted
with 2.5 ml of sterile saline. Five injections were done
for each patient, two injections (2  4 U) were given
1 cm superior to the inferior border of the mandible,
two other injections of units (2  4 U) were given1 cm
inferior to the inferior border of the zygomatic arch
and a fifth injection (1  4 U) was given in the center
of the masseter muscle [20,21] (Fig. 2). Injection of
temporalis muscle was best done just above the level of
the zygomatic arch at the junction of the scalp and non-
hair bearing temporal skin [22,23]. Three points of
injections of 4 units (3  4 U) were given 1 cm inferior
to the origin of the temporalis muscle (Fig. 3).
Aspiration before injection was done, then slow
intramuscular injection was done with bevel of the
needle toward skin, inserting whole needle in the
muscle with 45 angulation with skin which assure
least trauma and pain. Follow up scores obtained by the
questionnaire, clinical examination according to Di
and EMG analysis, MIO at 1, 2, 3 and 6 months in-
tervals after injection (Figs. 4 and 5).Fig. 1. Diagramatic illustration for injection points of masse-
ter&temporalis muscles.
Fig. 2. Points of injection of masseter muscle.
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- Range of mandibular motion;
Normal rang of movement. 0
Slightly impaired mobility. 1
Severely impaired mobility. 5
- TMJ function impairment;
Smooth movement without sound and deviation on
opening and closing 0
TMJ sound in one or both joints and/or
deviation  2 mm on opening or closing movement. 1
Locking and/or luxation of TMJ. 5
- Muscle tenderness during palpation;
No tenderness to palpation. 0
Tenderness to palpation in 1e3 palpation sites. 1
Tenderness to palpation in 4 or more sites. 5
- TMJ pain during palpation;
No tenderness to palpation. 0
Tenderness to palpation laterally. 1
Tenderness to palpation posteriorly. 5Fig. 3. Points of injection of temporalis muscle.- Pain during mandibular movement;
No pain on movement. 0
Pain on 1 movement. 1
Pain on 2 or more movement. 5
The individuals were classified in four groups:
Di-0: 0 points e Individuals clinically free from
dysfunction symptoms;
Di-I: 1 to 4 points e Individuals with mild dysfunction
symptoms;
Di-II: 5 to 9 points e Individuals with moderate
dysfunction symptoms;
Di-III: 10 to 25 points e Individuals with severe
dysfunction symptoms
3. Results
3.1. Clinical results: (Tables 1e3) & (Figs. 1 and 2)
Preoperatively, MIO ranged from 19 to 28 mm.
After 6 months (end of observation period), it was
ranged from 35 to 45 mm. There were statistically
significant differences in MIO between preoperative
value and at the end of observation period of the study,
where P-value was 0.001.
There was statistically non-significant difference in
clicking between preoperative and post-operative value
at the different observation periods of the study where
P-value was 0.067.
The Di score preoperatively was III which indicate
severe dysfunction for all patients (100%). At the end
of the observation period there were half patients 50%
with Di:0 and rest (50%) with Di:I. There were sta-
tistically significant difference in Di score between
preoperative and postoperative values at the different
observation periods were P-value was 0.031.
3.2. Electromyographic results
The preoperative surface EMG recording of
masseter muscle of the healthy side which considered
control group ranged from 0.20 to 0.77 mv, while at the
affected side it ranged from 0.38 to 1.17 mv. The
difference between healthy and affected side of
masseter muscle was statistically significant.
At the end of the period of the study, surface EMG
recording of the healthy side of masseter muscle was
ranged from 0.20 to 0.77 mv and at the affected side
was ranged from 0.30 to 0.75 mv. There were no sta-
tistically significant differences in surface EMG
recording between healthy and affected side at the end
of observation period.
Fig. 4. Photographs of patient no (4) Showing maximal mouth opening after injection & different periods of study, A before injection, B after one
month, C after two months, D after three months and E after six months.
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poralis muscle of the healthy side which considered
control group ranged from 0.23 to 0.60 mv, while at the
affected side it ranged from 0.40 mv to 1.10. The dif-
ference between healthy and affected side of temporalis
muscle preoperatively was statistically significant. At
the end of the period of the study surface EMG
recording of healthy side of temporalis muscle ranged
from 0.23 to 0.60 mv and at the affected side was
ranged from 0.32 to 0.70 mv of. There were statisticallyFig. 5. Bargraph showing decrease in clicking preoperative, after injesignificant differences between healthy and affected
side of the muscle at end of observation period.
4. Discussion
BTX-A is a useful new therapeutic agent which has
been used successfully for treatment of many painful
clinical disorders by direct injection in the painful area
[4,24]. Therefore the aim of this study was to evaluate
the clinical outcomes and the effects of intramuscularction and during the different observation periods of the study.
Table 1
Statistical analysis of Helkimo clinical dysfunction index of the
affected side at different observation periods of the study.
(Di) 0 I II III
N % N % N % N %
Preoperative 0 0.00 0 0.00 0 0.00 10 100.00
After 1 mth 0 0.00 7 70.00 3 30.00 0 0.00
After 2 mths 1 10.00 9 90.00 0 0.00 0 0.00
After 3 mths 3 30.00 6 60.00 1 10.00 0 0.00
After 6 mths 5 50.00 5 50.00 0 0.00 0 0.00
Chi-square X2 13.852
P-value 0.031a
a Statistically significant difference at 5% level.
Table 2
Statistical analysis of electromyographic measurements of masseter
muscle of the affected side at different observation periods of study.
Masseter muscle Difference Paired t-test
Range Mean ± SD Mean SD t P-value
Preoperatively 0.38e1.17 0.77 ± 0.25
After 1 mth 0.30e0.93 0.56 ± 0.20 0.21 0.11 6.02 <0.001a
After 2 mths 0.20e0.70 0.44 ± 0.16 0.34 0.20 5.42 <0.001a
After 3 mths 0.27e0.73 0.46 ± 0.15 0.32 0.18 5.40 <0.001a
After 6 mths 0.30e0.75 0.52 ± 0.16 0.25 0.15 5.30 <0.001a
a Statistically significant difference at 5% level.
Table 3
Statistical analysis of electromyographic measurements of temporalis
muscle of the affected side at different observation period of the study.
Temporalis muscle Difference Paired t-test
Range Mean ± SD Mean SD t P-value
Preoperatively 0.40e1.10 0.70 ± 0.19
After 1 mth 0.33e0.73 0.48 ± 0.12 0.22 0.13 5.29 <0.001a
After 2 mths 0.27e0.50 0.36 ± 0.08 0.34 0.20 5.46 <0.001a
After 3 mths 0.30e0.60 0.43 ± 0.11 0.27 0.15 5.67 <0.001a
After 6 mths 0.32e0.70 0.52 ± 0.12 0.18 0.11 4.94 <0.001a
a Statistically significant difference at 5% level.
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muscles extra orally for management of MPS.
Helkimo clinical dysfunction index was used to
diagnose and evaluate the efficacy of treatment of MPS
with BTX-A in this study by recording the progress of
its five criteria which was adopted and appreciated by
Khedr, Suzana et al., who used Di for diagnosis and
assessment of TMD patients during evaluation period
of their studies [12e15].
In this study surface EMG was used for measure-
ment of muscular activity, which considered an
important component of diagnosis and biofeedback
treatment of MPS [25e29]. Temporalis and masseter
muscles were evaluated at maximal voluntarycontraction, where clinical observations and electro-
myographical findings complemented each other. This
was in agreement with Yang, Zhang [30], who reported
that EMG is a valuable research tool in diagnosis of
TMD and in evaluating the effectiveness of treatment.
Accordingly, we use this technique in this study for
assessment of muscle activity, where all injections of
BTX-Awere intramuscular as verified by surface EMG
guidance, extra orally without any anesthetic agent
using insulin syringe. The procedure was painless,
assessment were carried out after 1, 2, 3and 6 months
[31,32].
9 patients were females and only one was male.
This female predilection can be explained on the
believe that females are more related to increased
psychological stress as well as excessive muscle
function. This was in agreement with the psychological
theory of Gordon et al. [33], who reported that MPS is
common in female in second to fifth decades of life
because of different perception and response to
symptoms compared to men.
The analysis of clinical and myographical results
showed an improvement in the mean value of MIO
from 22.6 mm before injection to 38.5 mm at the end
of the study period. This was accompanied with an
improvement in the range of mandibular motion. These
might be attributed to the increased muscular relaxa-
tion, reduction of inflammation and disappearance of
pain which was essentially described by Freund et al.,
[4,20].
In this study there were only 5 patients suffering
from clicking which disappeared after one month for
three patients, and after two months for the other two
patients, but recurrence had occurred to these two pa-
tients associated with pain in the temporal region at the
end of study period. This agree with Schwartz et al.,
[4], who reported that although clicking was signifi-
cantly reduced midway through his study, it had
returned to pretreatment value by the final two as-
sessments. The two patients with recurrent clicking
had received a second injection in temporalis muscle
only after three months due to recurrence of pain at-
tacks in temporalis muscle only. This agrees with
Cheshire et al. [18], who described that most in-
dividuals in his study have had only two series of in-
jections at most.
Another observation in this study was that all pa-
tients had improved functional index score, marked
reduction in pain and muscle tenderness as revealed by
Di, from Di: III before injection to Di: 0 and Di: I at
the end of observation period, which was adopted by
Khedr, Suzana [12e15].
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ment appeared to be more useful and reliable method
in determining the prognosis of treatment. This was in
agreement with the present study, where the average
level of muscle activity of temporalis muscle during
maximal biting decreased. There was statistically sig-
nificant difference between healthy and affected side of
the muscle at end of observation period coinciding
with improvement of the signs and symptoms of MPS.
Unlike masseter muscle, where there was no statisti-
cally significant difference in surface EMG recording
between healthy and affected side at the end of
observation period, which might attributed to improper
dose in relation to size of muscle. This was in agree
with Freund, Schwartz [4,8,20], who reported that
further improvement was noticed after carrying out the
treatment one more time.
The results of this study revealed a gradual and
well established decrease in muscular activity which
was statistically significant during the study period for
both masseter and temporalis muscles. This agree with
Karacalar et al. [34], who reported reduction in MVC
in all main out comes measures between pretreatment
assessment and the different follow up assessment.
Similarly Isberg et al., [35] in their studies found that
the improvement coincided with objective and sub-
jective weakening of masseter and temporalis
muscles.
There were no side effects either at the injection
visit or during observation period neither local nor
systemic. Unlike Clark, Issac [36,37], who reported an
itching at the injection site, headache, dry mouth and
flu-like symptoms as systemic side effects. They
explained these side effects due to improper muscle
targeting of BTX-A, which lead to escape of the so-
lution in to neighboring anatomical structures pro-
ducing undesirable effects [38].
5. Summary and conclusion
In the last decades dramatic advances have been
made in understanding the causes of facial pain related
to TMD. Because of the multifactorial nature of the
disease, the treatment methodology varies greatly
among clinicians but had the same aim of control of
pain and discomfort. BTX.A is safe, well tolerated and
can be used for management MPS. There were no side
effects, neither local nor systemic from BTX-A injec-
tion. Due to great controversy about BTX-A, further
researches is necessary on the exact mechanism of
BTX-A for chronic pain management and its role in
multifactorial treatment. Future researches shouldinclude expanding the domain of treatable diseases,
comparing injection intervals, formation of antibodies,
cost and complications.
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